Butoconazole clinical pharmacology: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) Created page with "__NOTOC__ {{Butoconazole}} {{CMG}}; {{AE}} {{AZ}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = GYNAZOLE 1 (BUTOCONAZOLE NITRATE) CREAM [THER-RX..." |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = GYNAZOLE 1 (BUTOCONAZOLE NITRATE) CREAM [THER-RX CORPORATION] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5eebfdbb-4800-4f59-9eaa-93e1c02b7b5f | publisher = | date = | accessdate = }}</ref> | ==Clinical Pharmacology== | ||
Following vaginal administration of butoconazole nitrate vaginal cream, 2% to 3 women, 1.7% (range 1.3-2.2%) of the dose was absorbed on average. Peak plasma levels (13.6-18.6 ng radioequivalents/mL of plasma) of the drug and its metabolites are attained between 12 and 24 hours after vaginal administration<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = GYNAZOLE 1 (BUTOCONAZOLE NITRATE) CREAM [THER-RX CORPORATION] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5eebfdbb-4800-4f59-9eaa-93e1c02b7b5f | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 04:11, 10 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Clinical Pharmacology
Following vaginal administration of butoconazole nitrate vaginal cream, 2% to 3 women, 1.7% (range 1.3-2.2%) of the dose was absorbed on average. Peak plasma levels (13.6-18.6 ng radioequivalents/mL of plasma) of the drug and its metabolites are attained between 12 and 24 hours after vaginal administration[1]
References
Adapted from the FDA Package Insert.